Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
CorMedix Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
CRMD
Nasdaq
2834
cormedix.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for CorMedix Inc.
Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates
- Aug 4th, 2026 3:15 pm
CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
- Jul 29th, 2026 6:30 am
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
- Jul 9th, 2026 3:25 pm
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue?
- Jul 8th, 2026 7:15 am
CRMD's Growth Story Expands Beyond DefenCath Into New Trends
- Jun 30th, 2026 9:10 am
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
- Jun 30th, 2026 9:07 am
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
- Jun 30th, 2026 9:04 am
CorMedix (CRMD) Stock Could Be 27.8% Undervalued After Q1 Results And Raised Outlook
- Jun 17th, 2026 5:12 am
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And DefenCath Momentum - Learn Why
- Jun 16th, 2026 12:12 am
CorMedix Inc. (CRMD) Reports Q1 2026 Results
- Jun 13th, 2026 12:07 pm
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in MinocinĀ® Patent Litigation
- Jun 8th, 2026 6:30 am
CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms
- May 22nd, 2026 4:04 am
Does Strong Q1 Beat And Raised Outlook Transform The Bull Case For CorMedix (CRMD)?
- May 17th, 2026 1:08 pm
A Look At CorMedix (CRMD) Valuation After Strong Q1 2026 Results And Raised Full Year Guidance
- May 16th, 2026 6:11 am
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
- May 15th, 2026 8:11 am
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
- May 15th, 2026 6:30 am
Cormedix Inc (CRMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
- May 14th, 2026 5:02 pm
CorMedix Inc. Q1 2026 Earnings Call Summary
- May 14th, 2026 2:45 pm
CorMedix (CRMD) Q1 2026 Earnings Transcript
- May 14th, 2026 12:44 pm
CorMedix Q1 Earnings Call Highlights
- May 14th, 2026 8:07 am
Scroll